We are live on
!
Find out more
VM
VHCP Management Portfolio holdings
AUM
$93M
1-Year Est. Return
10.04%
This Fund
S&P 500
This Quarter
Est. Return
-7.09%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.5M
AUM Growth
-$18.7M
(-16%)
Cap. Flow
-$5.48M
Cap. Flow
% of AUM
-5.68%
Top 10 Holdings %
Top 10 Hldgs %
85.26%
Holding
24
New
1
Increased
2
Reduced
–
Closed
1
Avg Time Held
5
quarters
Top 10 Avg Time Held
4.1
quarters
Top 20 Avg Time Held
5.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$1.37M |
| 2 |
Arcturus Therapeutics
ARCT
|
+$625K |
| 3 |
Spyre Therapeutics
SYRE
|
+$46K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$7.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.96% |
| 2 | Miscellaneous | 32.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$74.9M
| $19.8M | 20.5% |
1,095,734
| – | – |
2013 Q3
11 quarters
|
|
2
Coherus Oncology
CHRS
$162M
| $10.3M | 10.69% |
611,010
| – | – |
2014 Q4
6 quarters
|
|
|
AVDL
3
DELISTED
Avadel Pharmaceuticals
AVDL
| $5.37M | 5.57% |
500,000
| – | – |
2014 Q1
9 quarters
|
|
4
Larimar Therapeutics
LRMR
$273M
| $3.61M | 3.74% |
50,176
| – | – |
2014 Q2
8 quarters
|
|
5
DELISTED
Adverum Biotechnologies
ADVM
| $3.48M | 3.61% |
110,274
| – | – |
2014 Q3
7 quarters
|
|
|
6
BioCryst Pharmaceuticals
BCRX
$2.16B
| $2.85M | 2.96% |
1,005,104
+442,161
| +79% | +$1.37M |
2016 Q1
1 quarter
|
|
|
7
Arcturus Therapeutics
ARCT
$382M
| $2.8M | 2.9% |
89,045
+19,831
| +29% | +$625K |
2015 Q1
5 quarters
|
|
8
Lipocine
LPCN
$13.9M
| $2.58M | 2.68% |
49,995
| – | – |
2014 Q2
8 quarters
|
|
|
SIOX
9
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $2.36M | 2.45% |
23,014
| – | – |
2016 Q1
1 quarter
|
|
10
Akari Therapeutics
AKTX
$19.6M
| $2.14M | 2.21% |
198
| – | – |
2015 Q3
3 quarters
|
|
11
BeOne Medicines Ltd
ONC
$39.7B
| $1.52M | 1.58% |
51,000
| – | – |
2016 Q1
1 quarter
|
|
|
OCRX
12
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $1.51M | 1.57% |
796,550
| – | – |
2013 Q4
10 quarters
|
|
13
PDS Biotechnology
PDSB
$104M
| $1.36M | 1.41% |
6,750
| – | – |
2015 Q4
2 quarters
|
|
14
Oruka Therapeutics
ORKA
$5.35B
| $1.34M | 1.39% |
2,141
| – | – |
2015 Q2
4 quarters
|
|
|
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.21M | 1.26% |
72,990
| – | – |
2015 Q4
2 quarters
|
|
16
Ascendis Pharma A/S
ASND
$15B
| $1.19M | 1.24% |
90,000
| – | – |
2015 Q1
5 quarters
|
|
|
STML
17
DELISTED
Stemline Therapeutics, Inc.
STML
| $917K | 0.95% |
135,420
| – | – |
2014 Q3
7 quarters
|
|
18
CytomX Therapeutics
CTMX
$547M
| $656K | 0.68% |
64,200
| – | – |
2015 Q4
2 quarters
|
|
19
Regenxbio
RGNX
$534M
| $420K | 0.44% |
52,500
| – | – |
2015 Q3
3 quarters
|
|
|
SRRA
20
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $112K | 0.12% |
1,401
| – | – |
2015 Q3
3 quarters
|
|
|
21
Spyre Therapeutics
SYRE
$7.93B
| $29K | 0.03% |
+240
| New | +$46K |
2016 Q2
0 quarters
|
|
|
ANAC
22
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| – | – |
-140,756
| Closed | -$7.52M | – |
|
Similar funds
QGI
KC
RSCM
ZC
TF
SAM
NA
NCIM
VHCP Management's Q2 2016 Portfolio in Review
As of Q2 2016, VHCP Management held 24 positions worth $96.5M, down 16% from $115M the previous quarter. Its ten largest holdings account for 85% of the portfolio.
VHCP Management withdrew a net $5.48M in Q2 2016, closing 1 position. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $7.52M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 67% a quarter earlier, followed by Miscellaneous.
Against the trend, VHCP Management opened a new position in Spyre Therapeutics worth $29K.
- VHCP Management's largest Q2 2016 buy was Spyre Therapeutics: 240 shares worth $29K.
- VHCP Management added most to BioCryst Pharmaceuticals in Q2 2016, an estimated $1.37M increase.
- VHCP Management fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $7.52M.
- VHCP Management's ten largest holdings make up 85% of its $96.5M portfolio in Q2 2016.
- VHCP Management opened 1 new position and closed 1 in Q2 2016.
- VHCP Management's portfolio value fell 16% quarter-over-quarter to $96.5M.
Based on VHCP Management's 13F filing for Q2 2016, filed 12 Aug 2016.